Genmab A/S experienced a significant boost during the pre-market trading after
UBS raised its target price by 3.52%. The Danish biotechnology company's shares have also been favorably reviewed by other financial institutions such as
H.C. Wainwright and
Truist Securities, who have both increased their projected stock price for the company.
Capital increases have bolstered Genmab, largely as a result of the
employee warrant exercise. The firm's financial growth is largely due to its continued success in various clinical trials, including the
epcoritamab development program. Genmab's positive
H1 2025 revenue growth completes a share buyback amidst strategic advancements, and its
cervical cancer study has been highlighted as a possible game-changer in the industry. However, despite overall positive prospects, Deutsche Bank has cut Genmab's stock price target, and
Genmab A/S was among the worst-performing biotech stocks in 2024.
Genmab Stocks News Analytics from Thu, 21 Nov 2024 08:00:00 GMT to Fri, 15 Aug 2025 12:00:09 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
